approval
savePLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: SOLUTION. Route: INTRAVENOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 3
same company · ±60 days · 6
- approvallutetium Lu 177 vipivotide tetraxetan: PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approvalMar 28, 2025
- approvalatrasentan hydrochloride: VANRAFIA (ATRASENTAN HYDROCHLORIDE) — FDA approvalApr 2, 2025
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025
- approvalSpexotras: MEKINIST (TRAMETINIB) — FDA approvalMar 19, 2025
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalMar 19, 2025
comments(0)
5-min edit window · permanent after that